Singapore markets closed

Clene Inc. (CLNN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.3700-0.0156 (-4.05%)
At close: 04:00PM EDT
0.3704 +0.00 (+0.11%)
After hours: 07:23PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.3856
Open0.3920
Bid0.3666 x 100
Ask0.3805 x 200
Day's range0.3700 - 0.3920
52-week range0.2500 - 1.0900
Volume311,132
Avg. volume887,576
Market cap47.521M
Beta (5Y monthly)0.49
PE ratio (TTM)N/A
EPS (TTM)-0.4700
Earnings date12 Aug 2024 - 16 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.00
  • GlobeNewswire

    Clene to Present at Upcoming May Conferences

    SALT LAKE CITY, May 14, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis and multiple sclerosis, today announced that it will participate in the following investor conferences in May. Mizuho Neuroscienc

  • Simply Wall St.

    Clene First Quarter 2024 Earnings: Misses Expectations

    Clene ( NASDAQ:CLNN ) First Quarter 2024 Results Key Financial Results Net loss: US$11.1m (loss narrowed by 5.9% from...

  • GlobeNewswire

    Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights

    Data from long-term extension of Phase 2 VISIONARY-MS clinical trial of CNM-Au8® demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p<0.05)Peer-reviewed publication characterized the protein corona of CNM-Au8Company received sub-award of $7.3 million from NIH grant for ALS Expanded Access ProgramCash, cash equivalents and marketable securities of $27.9 million as of March 31, 2024 SALT LAKE CITY, May 08, 2024 (GLOB